Tuznue™ (Trastuzumab biosimilar)

Tuznue™ (Trastuzumab biosimilar)
Product Description

Tuznue™ is a biosimilar of Herceptin® (trastuzumab), developed to offer a more cost-effective therapeutic alternative for patients. It maintains comparable efficacy and safety profiles to the original branded medication. Tuznue™ is indicated for the treatment of patients with HER2-positive metastatic breast cancer (MBC), HER2-positive early breast cancer (EBC), and HER2-positive metastatic gastric cancer (MGC). Tuznue™ has been granted Marketing Authorisation by the European Commission.

Read more Show less

Prestige Biopharma Limited

  • Country/Region:
    Singapore
  • On CPHI since:
    2018
  • Employees:
    250 - 499
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Categories
more categories Show less

Prestige Biopharma Limited

  • Country/Region:
    Singapore
  • On CPHI since:
    2018
  • Employees:
    250 - 499
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
View company profile

More Products from Prestige Biopharma Limited (3)

  • HD204 (Bevacizumab biosimilar)

    Product HD204 (Bevacizumab biosimilar)

    This is a biosimilar candidate of bevacizumab (Avastin®). Bevacizumab is used to treat many different types of cancer (often as first-line therapy) including metastatic colorectal cancer, non-small-cell lung cancer (NSCLC), renal cell cancer, ovarian cancer and metastatic breast cancer. Global Phase 3 ...
  • PBP1502 (Adalimumab biosimilar)

    Product PBP1502 (Adalimumab biosimilar)

    This is a biosimilar candidate of adalimumab (Humira®). Adalimumab is used to treat many inflammatory conditions in adults, such as rheumatoid arthritis. Phase 1 IND approved in Spain and the study is currently ongoing.

  • PBP1510 (INN: Ulenistamab)

    Product PBP1510 (INN: Ulenistamab)

    PBP1510 is a first-in-class monoclonal antibody drug developed by Prestige Biopharma Limited against pancreatic adenocarcinoma up-regulated factor (PAUF), a protein that is overexpressed in pancreatic adenocarcinoma. PAUF is involved in promoting tumor growth, invasion, and metastasis, in the evasion o...